Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Interest Expenses (2020 - 2021)

VYNE Therapeutics' Interest Expenses history spans 2 years, with the latest figure at $3.5 million for Q3 2021.

  • For Q3 2021, Interest Expenses rose 218.13% year-over-year to $3.5 million; the TTM value through Jun 2022 reached $3.5 million, down 20.85%, while the annual FY2021 figure was $5.6 million, 27.79% up from the prior year.
  • Interest Expenses reached $3.5 million in Q3 2021 per VYNE's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $3.5 million in Q3 2021 to a low of $1.1 million in Q1 2021.